The DOI matches its Crossref record.
Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion
Open accessAbstract
This paper, for the first time, demonstrates that exposure of cells to the poly(ethylene oxide)-poly(propylene oxide) block copolymer, Pluronic P85, results in a substantial decrease in ATP levels selectively in MDR cells. Cells expressing high levels of functional P-glycoprotein (MCF-7/ADR, KBv; LLC-MDR1; Caco-2, bovine brain microvessel endothelial cells [BBMECs]) are highly responsive to Pluronic treatment, while cells with low levels of P-glycoprotein expression (MCF-7, KB, LLC-PK1, human umbilical vein endothelial cells [HUVECs] C2C12 myoblasts) are much less responsive to such treatment. Cytotoxicity studies suggest that Pluronic acts as a chemosensitizer and potentiates cytotoxic effects of doxorubicin in MDR cells. The ability of Pluronic to inhibit P-glycoprotein and sensitize MDR cells appears to be a result of ATP depletion. Because many mechanisms of drug resistance are energy dependent, a successful strategy for treating MDR cancer could be based on selective energy depletion in MDR cells. Therefore, the finding of the energy-depleting effects of Pluronic P85, in combination with its sensitization effects is of considerable theoretical and practical significance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00009-3 · Cited by 1,474
Self-citationDevelopment of exosome-encapsulated paclitaxel to overcome MDR in cancer cells
Kim, M. S., Haney, M. J., Zhao, Y., Mahajan, V., Deygen, I., Klyachko, N. L., Inskoe, E., Piroyan, A., Sokolsky, M., Okolie, O., et al. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.10.012 · Cited by 1,410
Self-citationBatrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.013 · Cited by 1,278
“Selective suppression of energy production along with the membrane fluidization resulted in inhibition of drug-efflux pumps and strong sensitization of MDR cancer cells to the action of chemotherapeutic drugs in vitro [57].”
BackgroundInfluentialSelf-citationAmphiphilic block copolymers for drug delivery
Adams, M. L., Lavasanifar, A., & Kwon, G. S. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10397 · Cited by 1,078
Nishiyama, N., & Kataoka, K. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.05.006 · Cited by 1,052
Application of Nanotechnology in Cancer Therapy and Imaging
Wang, X., Yang, L., Chen, Z., & Shin, D. M. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0003 · Cited by 700
Pluronic® block copolymers for overcoming drug resistance in cancer
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00047-9 · Cited by 636
Self-citationXu, W., Ling, P., & Zhang, T. (2013) · Journal of Drug Delivery · doi:10.1155/2013/340315 · Cited by 595
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
Lu, Y., & Park, K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.08.042 · Cited by 572
“In studies involving TPGS and poloxamers, improvement in permeability was seen at polymer concentrations below CMC and maximal at concentrations just below CMC (Chang et al., 1996; Batrakova et al., 1998, 2001).”
Peetla, C., Stine, A., & Labhasetwar, V. (2009) · Molecular Pharmaceutics · doi:10.1021/mp9000662 · Cited by 559
Pitto-Barry, A., & Barry, N. P. E. (2014) · Polym. Chem. · doi:10.1039/c4py00039k · Cited by 464
Recent progress in biomedical applications of pluronic (PF127): Pharmaceutical perspectives
Akash, M. S. H., & Rehman, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.032 · Cited by 394
Polymeric micelles for oral drug delivery
Gaucher, G., Satturwar, P., Jones, M.-C., Furtos, A., & Leroux, J.-C. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.06.007 · Cited by 389
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382
“…including inhibition of drug efflux transporters, abolishment of drug sequestration in acidic compartments, inhibition of the glutathione (GSH)/glutathione (GST) detoxification system and reduction of ATP selectively in MDR cells (Venne et al, 1996; Batrakova et al, 2001; Kabanov et al, 2002).”
BackgroundSelf-citationPluronic® block copolymers: novel functional molecules for gene therapy
Kabanov, A. V., Lemieux, P., Vinogradov, S., & Alakhov, V. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00018-2 · Cited by 375
Self-citationKabanov, A. V., Batrakova, E. V., & Miller, D. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00176-x · Cited by 325
Self-citationShafei, A., El-Bakly, W., Sobhy, A., Wagdy, O., Reda, A., Aboelenin, O., Marzouk, A., El Habak, K., Mostafa, R., Ali, M. A., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.059 · Cited by 318
Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress
Dong, X., & Mumper, R. J. (2010) · Nanomedicine · doi:10.2217/nnm.10.35 · Cited by 317
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
Self-citationDong, X., Mattingly, C. A., Tseng, M. T., Cho, M. J., Liu, Y., Adams, V. R., & Mumper, R. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2747 · Cited by 290
Collnot, E.-M., Baldes, C., Wempe, M. F., Kappl, R., Hüttermann, J., Hyatt, J. A., Edgar, K. J., Schaefer, U. F., & Lehr, C.-M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp060121r · Cited by 280
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders
Kabanov, A. V., & Gendelman, H. E. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.014 · Cited by 277
Self-citationPolymeric micelles in oral chemotherapy
Bromberg, L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.01.018 · Cited by 264
Multidrug resistance: Physiological principles and nanomedical solutions
Kunjachan, S., Rychlik, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.018 · Cited by 259
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Kirtane, A. R., Kalscheuer, S. M., & Panyam, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.001 · Cited by 258
Pluronics and MDR reversal: an update
Alakhova, D. Y., & Kabanov, A. V. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500298q · Cited by 224
Self-citationTang, R., Ji, W., Panus, D., Palumbo, R. N., & Wang, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.12.005 · Cited by 202
Ultrasonically triggered drug delivery: Breaking the barrier
Husseini, G. A., Pitt, W. G., & Martins, A. M. (2014) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.07.051 · Cited by 87
Novel polymeric micelles for drug delivery: Material characterization and formulation screening
Janas, C., Mostaphaoui, Z., Schmiederer, L., Bauer, J., & Wacker, M. G. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.05.029 · Cited by 36
Metadata
- Authors
- Batrakova, E. V., Li, S., Elmquist, W. F., Miller, D. W., Alakhov, V. Y., & Kabanov, A. V.
- Venue
- British Journal of Cancer
- Published
- 2001-12
- Volume
- 85
- Issue
- 12
- Pages
- 1987-1997
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1963500271
- Cited by
- 229
- References
- 0
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.